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RFLAT-1: A New Zinc Finger Transcription Factor
that Activates RANTES Gene Expression
in T Lymphocytes
Subsequently, several groups showed that the C-C che-
mokine receptor CC-CKR5, which selectively binds to
these chemokines, is a coreceptor for HIV entry into
target cells (Alkhatib et al., 1996; Choe et al., 1996; Deng
et al., 1996; Doranz et al., 1996; Dragic et al., 1996).
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Based on these observations, RANTES and its receptorsStanford, California 94305-5208
have been evaluated as potential therapeutic targets for
immune-related diseases and AIDS (Nelson and Kren-
sky, 1998). Thus, understanding the molecular basis
Summary for control of RANTES gene expression, especially in T
cells, may help in the design and development of novel
RANTES (Regulated upon Activation, Normal T cell immunotherapies for a variety of diseases.
Expressed and Secreted) is a chemoattractant cyto- The RANTES gene was originally identified as a cDNA
kine (chemokine) important in the generation of in- during a general screen for genes expressed at a ªlateº
flammatory infiltrate and human immunodeficiency stage of T cell activation (Schall et al., 1988). When
virus entry into immune cells. RANTES is expressed peripheral T cells are triggered through the T cell recep-
late (3±5 days) after activation in T lymphocytes. Using tor, they enter a 3±7 day maturation process that in-
expression cloning, we identified the first ªlateº T lym- volves commitment, proliferation, and terminal differen-
phocyte associated transcription factor and named it tiation (Crabtree, 1989; Ullman et al., 1990). Commitment
ªRANTES Factor of Late Activated T Lymphocytes-1º occurs rapidly after the binding of the T cell receptor with
(RFLAT-1). RFLAT-1 is a novel, phosphorylated, zinc the specific antigen and is accompanied by immediate
finger transcription factor that is expressed in T cells induction of a number of genes such as protooncogenes
3 days after activation, coincident with RANTES ex- and interleukins. Once T cells are activated, they syn-
pression. While Rel proteins play the dominant role in thesize new DNA and proliferate. At 3±5 days after acti-
vation, T cells enter the phase of terminal differentiation,RANTES gene expression in fibroblasts, RFLAT-1 is a
characterized by the expression of functional genes andstrong transactivator for RANTES in T cells.
the generation of effector cells such as cytotoxic T
lymphocytes or helper T cells. Nearly 100 genes haveIntroduction
been shown to be induced ªearlyº upon T cell activation.
Studies on one of these, interleukin-2, led to the identi-RANTES (Regulated upon Activation, Normal T cell Ex-
fication of a transcription factor NFAT (nuclear factor ofpressed and Secreted) is a member of the large and
activated T lymphocytes), which mediates T cell activa-growing family of immunoregulatory cytokines called
tion (Shaw et al., 1988; Crabtree and Clipstone, 1994).
chemokines. The functions of chemokines include at-
The elucidation of the calcineurin-NFAT signaling path-
tracting blood leukocytes to sites of inflammation (Bag- way provided insight into the mechanism of action of
giolini et al., 1997; Schluger and Rom, 1997), regulating the immunosuppressive drugs cyclosporin and FK506
leukocyte maturation, trafficking and homing, and the (Schreiber and Crabtree, 1992). Compared to the num-
development of lymphoid tissues (for recent review, see ber of genes identified as early genes, fewer genes are
Nelson and Krensky, 1998; Baggiolini, 1998). RANTES newly expressed at the T cell differentiation stage, and
belongs to the C-C chemokine subfamily. It is a potent the molecular basis of late expression is poorly under-
chemotactic agent for monocytes, T lymphocytes (Schall stood. Unlike other members of the chemokine family,
et al., 1990), eosinophils (Kameyoshi et al., 1992; Rot et which are expressed early (Ullman et al., 1990), RANTES
al., 1992), basophils (Dahinden et al., 1994), and natural mRNA is induced late (3±5 days) after T cell activation.
killer cells (Maghazachi et al., 1994; Taub et al., 1995). Together with the genes encoding perforin, granzymes
It also causes degranulation of basophils, respiratory A and B, and granulysin, it is expressed at high levels
burst in eosinophils, and activation of T cells (Kuna et in terminally differentiated T cell lines (Ortiz et al., 1997).
al., 1992; Alam et al., 1993; Bacon et al., 1995). Thus, This timing appears unique to T cells, as many other
RANTES appears to play an important role in both acute cell types, including fibroblasts, epithelial cells, and
and chronic phases of inflammation. monocytes/macrophages express RANTES within hours
RANTES and the closely related chemokines, macro- after stimulation (Ortiz et al., 1995). Studies on the
RANTES promoter and its cis-regulatory elements impli-phage inflammatory protein 1a (MIP-1a) and MIP-1b,
cate the involvement of late T cell transcription factorsmay also play a role in resistance to human immuno-
in this unique expression pattern (Nelson et al., 1996;deficiency virus (HIV) infection. Cocchi and colleagues
Ortiz et al., 1996). Work from our group led to the hy-showed that RANTES, MIP-1a, and MIP-1b inhibit infec-
pothesis that there is a ªswitchº of nuclear factors intion of HIV in CD81 T cells in vitro and that these chemo-
maturing T cells (Ortiz et al., 1997). However, these latekines are highly expressed in some patients who are
T cell transcription factors remain to be identified.HIV1 but do not progress to AIDS (Cocchi et al., 1995).
Here, we report the first cloning and characterization
of a late transcription factor, which we have designated
RFLAT-1 (RANTES Factor of Late Activated T Lympho-* To whom correspondence should be addressed (e-mail: mn.aln@
forsythe.stanford.edu). cytes-1). RFLAT-1 is a novel protein belonging to the
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Figure 1. Southwestern Analysis, Nucleotide
and Deduced Amino Acid Sequence of
RFLAT-1, and Zinc Finger Domain Compari-
son of RFLAT-1 with Other Proteins
(A) Diagram of regulatory regions in the 2195
RANTES promoter and their positions relative
to transcription start site 11.
(B) 50 mg each of nuclear extracts from rest-
ing PBL (day 0), PHA activated PBL at days
1±7, AJY-CTL, mature T tumor line Hut78, and
B lymphoblastoid JY cells were extracted and
separated by 10% SDS-PAGE. Nuclear pro-
teins were transferred onto a PVDF mem-
brane and hybridized with [g32P] labeled A/B
oligonucleotide. The membrane was washed
and an autoradiogram was made by exposure
to Amersham hyperfilm at 2808C for 3 days.
(C) Nucleotide and deduced amino acid se-
quence of RFLAT-1. The three zinc fingers are
underlined and the highly conserved cysteine
and histidine residues are shown in boxes.
(D) Comparison of the zinc finger domain of
RFLAT-1 to those of other proteins. Similar
amino acids are depicted by dashed lines.
The two cysteine and two histidine residues
for each zinc finger are boxed.
(E) Schematic diagram of the RFLAT-1 pro-
tein structure. The proline-rich putative trans-
activation domain, the three zinc fingers, and
the short basic region are represented by an
open box, three shadowed boxes, and a solid
box, respectively. The numbers indicate the
first and last amino acid of each domain.
TFIIIA-like zinc finger protein superfamily. RFLAT-1 spe- activity since point mutations or nonsense nucleotide
replacement decreases the activity by 90% (Nelson etcifically binds to the A site of the RANTES promoter
(Figure 1A). It is a component of protein complexes bind- al., 1996; Moriuchi et al., 1997). The A site binds both
Rel and non-Rel proteins, with the non-Rel protein beinging to the A/B site that are induced 3 days after T cell
activation. The RFLAT-1 protein itself is expressed in upregulated in T cell nuclear extracts on day 3 after
activation, coincident with RANTES message inductionT cells 3 days after activation. Reporter gene assays
demonstrate that RFLAT-1 is a strong activator of the (Nelson et al., 1996). The C site and E site also bind
nuclear proteins that are strongly induced between daysRANTES promoter in T cells. In contrast, Rel proteins
play the dominant role in RANTES gene expression in 3 and 5 after activation of normal peripheral blood T
cells (Ortiz et al., 1996).fibroblasts.
In order to identify the non-Rel protein binding to the
A site, Southwestern blotting was performed. NuclearResults
extracts from resting peripheral blood lymphocytes
(PBL), Phytohemagglutinin (PHA) P activated PBL onNon-Rel Proteins Bind to the A/B Site
of the RANTES Promoter different days, and other cell lines were separated by
SDS-PAGE and blotted on PVDF membranes. The mem-The RANTES promoter has been subdivided into five
regions (A-E) based upon deletion studies and reporter branes were hybridized with a radiolabeled oligonucleo-
tide corresponding to the A/B region of the RANTESgene assays (Figure 1A) (Nelson et al., 1993, 1996; Ortiz
et al., 1996). The A site is very important for the promoter promoter and several nuclear proteins were detected
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(Figure 1B). Proteins migrating at about 38 kDa, 75 kDa,
and 105 kDa were detected in PBL only at late activation
stages (days 3±7), showing kinetics similar to the factors
detected by electrophoretic mobility shift assays (EMSA)
(Nelson et al., 1996). When an oligonucleotide containing
three tandem A sites (A3) was used as the probe, the
38 kDa protein showed an even higher binding affinity
(data not shown).
Identification and Characterization of RFLAT-1
The results from the Southwestern analysis indicated
that expression cloning could be used to identify pro-
teins that bind to the A region of the RANTES promoter.
A lgt11 cDNA library was constructed using poly(A)1
RNA from PBL on day 5 after activation by PHA, and
the library was probed with radiolabeled A3 oligonucleo-
tides. Upon screening, a cDNA clone (880 bp) was identi-
fied that contained three contiguous zinc fingers defined
as a classical DNA binding motif (Mitchell and Tjian, Figure 2. Characterization of the RFLAT-1 Protein
1989). This clone was used to screen the original library (A) RFLAT-1 cDNA was subcloned into the pcDNA3.1 vector and
to obtain a longer cDNA (1430 bp), which contains an subjected to in vitro transcription and translation in the presence
of [35S]-Met. Aliquots of the translated products from pcDNA3.1 (laneopen reading frame of 864 bp defined by a potential
1) or pcDNA3.1-RFLAT-1 (lane 3) were separated by 10% SDS-ATG start codon (nucleotide 379±381), a TGA stop codon
PAGE. Other aliquots were treated with alkaline phosphatase for(nucleotide 1243±1245), and is flanked by 378 (59) and
1 hr at 378C before loading onto the gel (lane 2, pcDNA3.1 1 phos-
185 (39) untranslated nucleotide sequences (Figure 1C). phatase; lane 4, pcDNA3.1-RFLAT-1 1 phosphatase). The gel was
The first methionine is surrounded by a consensus Ko- fixed, dried, and exposed for autoradiography.
zak sequence (GCCCGCAGCATGG). A stop codon TGA (B) COS-7 cells were transfected with pcDNA3.1 (lane 2) or pcDNA3.1-
RFLAT-1 (lane 4). Thirty-six hours after transfection, cells were har-is found 43 bp upstream in-frame with the start codon.
vested and nuclear extracts were isolated. Aliquots of nuclear ex-This open reading frame encodes a 288 amino acid
tracts were treated with alkaline phosphatase for 1 hr at 378C (lanepolypeptide with a calculated molecular mass of 31,680
1, pcDNA3.1 1 phosphatase; lane 3, pcDNA3.1-RFLAT-1 1 phos-
daltons. A search of the GenBank database with the phatase). Each sample representing equal number of cells was re-
BLAST algorithm failed to identify any similar protein or solved by 10% SDS-PAGE and immunoblotted with anti-RFLAT-1.
cDNA sequence. Based on its function and expression,
we have named it RFLAT-1 (for RANTES Factor of Late
Activated T Lymphocytes-1). likely to be phosphorylated. To further confirm this,
COS-7 cells were transfected with pcDNA3.1-RFLAT-1The deduced amino acid sequence contains three
contiguous TFIIIA-like zinc-finger motifs at the C termi- and analyzed by Western blot for RFLAT-1 expression
using polyclonal antibodies generated against recombi-nus. This domain shows 73%, 72%, 65%, and 65% se-
quence similarity to those of Sp1 (Kadonaga et al., 1987), nant RFLAT-1. Bands at approximately 38 kDa and lower
were detected only in RFLAT-1 transfected cells, butSp3 (Kingsley and Winoto, 1992), EKLF (Bieker, 1996),
and BTEB (Sogawa et al., 1993) proteins, respectively not in empty vector transfected cells (Figure 2B). Alkaline
phosphatase treatment converted some, but not all, of(Figure 1D). Adjacent to the N terminus of the zinc finger
motif is a short sequence rich in basic amino acids, the slower migrating species into the faster migrating
form (Figure 2B). These results confirm that the RFLAT-1which does not show any obvious sequence homology
to the consensus sequence for the basic domain of cDNA clone contains the entire coding region of the
protein and also indicate that RFLAT-1 is phosphory-either Sp1 family members or helix-loop-helix-leucine
zipper proteins (Kadonaga et al., 1987; Fisher et al., lated.
1991). Outside of these domains, the RFLAT-1 protein
(1±145) is notably rich in proline (24/145), serine (10/ Tissue and Cellular Distribution of RFLAT-1
Northern blot analysis was performed using poly(A)1145), and alanine (30/145) residues, which are known to
constitute activation domains for a number of transcrip- RNA from 16 different adult human tissues. Two distinct
transcripts (5 and 7.5 kb) were evident in all of the tissuestion factors (Figure 1E) (Mitchell and Tjian, 1989).
To confirm that the 1430 bp cDNA clone encodes analyzed, with the greatest abundance in PBL and thy-
mus (Figure 3A). RFLAT-1 expression was also assayedthe full-length RFLAT-1 protein, the RFLAT-1 cDNA was
subcloned into the pcDNA3.1 vector and subjected to with poly(A)1 RNA from human cell lines of hematopoi-
etic origin and found to be widely expressed (Figure 3B).in vitro transcription and translation. The reaction pro-
duced a doublet protein band with an apparent molecu- The intracellular localization of the RFLAT-1 protein
was analyzed by immunofluorescence in COS-7 cellslar mass of 38 kDa that was not present when the control
vector was used (Figure 2A), confirming the accuracy of transiently transfected with RFLAT-1 cDNA. The overex-
pressed RFLAT-1 protein was primarily localized to thethe RFLAT-1 sequence. Alkaline phosphatase treatment
converted the slower migrating band to the faster mi- nuclear compartment of transfected COS-7 cells (Figure
4B). RFLAT-1 staining was blocked specifically by addi-grating form (Figure 2A), indicating that the two bands
are different forms of the protein, and that RFLAT-1 is tion of recombinant His6-RFLAT-1 (data not shown). When
Immunity
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A/B probe but not the A probe. His6-RFLAT-1 does not
bind to the E or C probes in the assays, consistent with
the results from the expression screening. Although the
A/B site is very similar to the consensus sequence of
the NF-kB binding site, and both the p50-p50 homodi-
mer and p65-p50 heterodimer bind to the A/B region
(Nelson et al., 1996; Moriuchi et al., 1997), His6-RFLAT-1
did not bind to the kB oligonucleotide (Figure 5A), which
contains the consensus NF-kB recognition sequence
derived from the immunoglobin promoter (Baeuerle and
Henkel, 1994).
To determine whether RFLAT-1 is present in the pro-
tein complex binding to the A/B region of the RANTES
promoter that is induced upon T cell activation, nuclear
extracts were isolated from resting and activated PBL
for supershift assays. Two prominent bands were de-
tected in the activated PBL nuclear extracts with the
A/B probe; band 2 shows later kinetics than band 1
(Figure 5B). Addition of polyclonal anti-RFLAT-1 to the
gel shift reaction mixture disrupted the complex forma-
tion for both band 1 and band 2 (Figure 5C), indicating
that RFLAT-1 is indeed present in both complexes. Simi-
lar results were obtained when either the A or B probe
was used (data not shown). The ability of the anti-
RFLAT-1 polyclonal antiserum to disrupt the DNA-pro-Figure 3. Tissue Distribution of RFLAT-1
tein complex was not surprising since the antiserum
(A) Northern blot analysis of poly(A)1 RNA from adult human tissues.
was raised against the C-terminal portion of RFLAT-1A prepared multi-tissue membrane (Clontech) was hybridized with
that contains the DNA-binding domain. Commercially[a32P] randomly labeled RFLAT-1 cDNA probe. The same membrane
was stripped and subsequently hybridized with a human b-actin available antibodies to other DNA binding proteins were
probe to normalize for the amount of RNA. also evaluated. Anti-p50, anti-p65, but not anti-c-rel,
(B) Northern blot analysis of 2 mg poly(A)1 RNA from different cell also supershifted both band 1 and band 2 (Figure 5C;
lines: PBL (day 5, PHA activated), AJY (CTL), Hut78 (mature T cell data not shown), demonstrating that NF-kB is also pres-
tumor), Jurkat (T cell tumor), JY (B lymphoblastoid), YT2C2 (NK-
ent in both of the DNA-protein complexes. Miyamoto etlike tumor), K562 (erythroleukemia), Raji (B lymphoma), and HeLa
al. (unpublished data) reported that Sp1 and Sp3 are(fibroblastoid). The same membrane was also hybridized with a
b-actin probe. components of the protein complex binding to the A/B
site that is induced by interleukin-1b in astrocytes. We
used the same antibodies to test whether Sp1 or Sp3
cells were simultaneously stained with anti-RFLAT-1 are present in T cell A/B-protein complexes. Neither
and propidium iodide, RFLAT-1 and stained DNA colo- anti-Sp1 nor anti-Sp3 supershifted or disrupted the A/B
calized in the nucleus (Figures 4C and 4D). The combi- DNA-protein complex, suggesting that Sp1 and its close
nation of cellular fractionation and Western blotting family members are not involved in the upregulation of
also shows the primary localization of RFLAT-1 in the RANTES expression in activated T lymphocytes.
nucleus of activated T cells (data not shown). For Jurkat, Nuclear extracts from other cell lines were also tested
RFLAT-1 is only detected in the nucleus (Figure 6B). for A site binding. Both RFLAT-1 mRNA and protein are
expressed in Jurkat, Hut78, JY, and HeLa cells (Figures
RFLAT-1 Binds DNA Sequences of the A Region 3B and 6B). Nuclear extracts from Hut78, a ªmatureº T
of the RANTES Promoter cell tumor line that constitutively expresses low levels
A carboxyl terminal portion of RFLAT-1, including the of RANTES, showed a similar A site binding pattern to
zinc finger DNA binding domain (nucleotides 550±1430), that of nuclear extracts from PBL activated for 7 days
was isolated through expression cloning using an oligo- with PHA. In contrast, nuclear extracts from Jurkat, JY,
nucleotide probe containing three tandem A sites of the and HeLa, which do not express RANTES, did not show
RANTES promoter. The same phage clones did not bind this pattern of binding to the A site (Figure 5D).
to the E or C site when a trimer E oligonucleotide or
tetramer C oligonucleotide were used as probes (data RFLAT-1 Is Expressed Late after T Cell Activation
not shown). To further demonstrate its DNA binding RFLAT-1 is a component of the protein complex binding
specificity, the C-terminal portion of RFLAT-1 (amino to the A/B region of the RANTES promoter. This complex
acids 59±288) was expressed as a His6-tagged recombi- is induced late (3±5 days) after T cell activation. To inves-
nant protein and used for EMSA (Figure 5A). Incubation tigate these kinetics, total RNA from resting and acti-
of His6-RFLAT-1 with the A/B and A probes, but not the vated PBL was isolated and RNA blots were probed
B probe, revealed retarded protein bands. It is likely that with the 880 bp RFLAT-1 cDNA fragment (nucleotides
binding of RFLAT-1 to the A site enhances cooperative 550±1430). Both transcripts (5 and 7.5 kb) were detected
binding of the protein to the B site, thereby accounting at comparable levels in resting and activated PBL (Fig-
ure 6A). Therefore, during T cell activation, the RFLAT-1for the lower mobility band seen in the EMSA using the
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Figure 4. Cellular Localization of RFLAT-1
COS-7 cells were transfected with pcDNA3.1
or pcDNA3.1-RFLAT-1. After 36 hours, the
transfected cells were fixed, permeabilized,
labeled with antigen purified anti-RFLAT-1,
and then stained with goat anti-rabbit FITC
and anti-FITC Alexa 488. All the cells were
simultaneously stained with propidium iodide
to reveal the nucleus. (A) A COS-7 cell trans-
fected with the pcDNA3.1 and stained with
anti-RFLAT-1. (B) A COS-7 cell transfected
with pcDNA3.1-RFLAT-1 and stained with
anti-RFLAT-1. (C) The same cell shown in (B)
stained with propidium iodide. (D) Colocaliza-
tion of RFLAT-1 (green) and stained DNA (red)
in the nucleus (yellow).
steady-state mRNA level is constant. Nuclear extracts mediated effect. When the C or E sites were disrupted,
RFLAT-1 mediated induction was also impaired, indicat-and cytoplasmic fractions were also isolated from quies-
cent and activated PBL for Western blot analysis. Pro- ing that these sites also play roles in transactivation.
However, this decrease is most likely not mediatedteins reactive with anti-RFLAT-1 antiserum migrating at
38 kDa and lower appeared in both PBL nuclear and through direct binding to RFLAT-1 (as shown in EMSA,
Figure 5A).cytoplasmic extracts only after day 3 of activation (Fig-
ure 6B), indicating that the RFLAT-1 protein is expressed To evaluate the role of RFLAT-1 in RANTES expres-
sion in non-T cells, RFLAT-1 cDNA and reporter geneat the late activation stage of T lymphocytes. Western
analysis was also performed for the NF-kB subunits p50 constructs were introduced into NIH3T3 fibroblasts.
RFLAT-1 also transactivated the RANTES promoter inand p65. Both p50 and p65 proteins were enriched in
the nucleus of activated T cells between day 3±5 after fibroblasts, but the fold induction was only about half
of that achieved in Jurkat T cells (Figure 7B). In addition,activation. In the cytoplasmic fractions, the protein lev-
els of p50 and its precursor p105 steadily increased only the A and B sites, but not the E and C sites, affected
RFLAT-1-mediated RANTES induction in fibroblasts.following cellular activation (Figure 6C), but cytoplasmic
p65 peaked at day 3 and then decreased. Conversely, This suggests that RFLAT-1 functions through different
mechanisms in Jurkat T cells and in NIH3T3 fibroblasts.nuclear p65 began to increase at day 5 (Figure 6D).
These results show that the NF-kB protein is also in- To further investigate this possibility and to dissect
the roles of RFLAT-1 and the NF-kB family members increased at the late stage of T cell activation, and this
increase is in part due to nuclear translocation. RANTES gene induction in different cell types, the cDNA
of the p65 subunit and the p50 subunit of the NF-kB
protein were also subcloned into pcDNA3.1 and cotrans-RFLAT-1 Functions as a Transactivator
for the RANTES Gene fected into either Jurkat T cells or NIH3T3 fibroblasts
for reporter gene assays (Figures 7C and 7D). In T cells,To investigate the role of RFLAT-1 in the expression
of RANTES, pcDNA3.1-RFLAT-1 was introduced into both RFLAT-1 and p65 induced RANTES gene expres-
sion, but RFLAT-1 was a much more potent transac-Jurkat T cells together with luciferase reporter con-
structs derived from the RANTES promoter. Cotransfec- tivator than p65, as shown by the greater degree of
induction (10-fold versus 3- to 4-fold) when the sametion of RFLAT-1 with the pGL2-R-luciferase construct
increased the promoter activity by 10-fold (Figure 7A), amount of plasmid was introduced (data not shown).
When RFLAT-1, p65, and p50 were simultaneously over-demonstrating that RFLAT-1 can function as a transacti-
vator for the RANTES promoter. A similar degree of expressed, a synergistic effect was observed (Figure
7C). Identical cotransfection assays were performed ininduction was observed when a reporter gene construct
containing only three A/B sites was used for the cotrans- NIH3T3 fibroblasts (Figure 7D). In this case, p65 played
the dominant role in the transactivation of RANTES genefection, indicating that RFLAT-1 recognizes the A/B se-
quences. This was confirmed with pGL2-R-luciferase expression. p65 transactivation activity was so strong
that it masked the effect of RFLAT-1 (40-fold inductionconstructs in which either the A site, the B site, or both
sites were replaced with nonsense oligonucleotides. Re- by p65 alone versus 5-fold induction by RFLAT-1 alone)
(Figure 7D). When all three cDNAs (RFLAT-1, p65, andplacement of the A site decreased the induction more
than replacement of the B site, indicating that the A p50) were overexpressed, RFLAT-1 enhanced the tran-
scriptional induction by p65, but this effect was notsite is more important than the B site in the RFLAT-1
Immunity
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Figure 5. DNA Binding Activity of RFLAT-1
(A) The C-terminal 880 bp portion of the
RFLAT-1 cDNA was subcloned into the
pET28a(1) vector to make a His6-tagged fu-
sion protein. The purified and refolded re-
combinant His6-RFLAT-1 was used for EMSA
with [g32P] end-labeled oligonucleotides as
indicated. Lane 1±5: 0 mg, 1.25 mg, 2.5 mg,
5 mg, and 10 mg of His6-RFLAT-1 was added
to the A/B probe, respectively. 5 mg of His6-
RFLAT-1 was used for lanes 7, 9, 11, 13, and
15. The reaction mixtures were separated on
a 8% nondenaturing polyacrylamide gel and
exposed for autoradiography.
(B) 1 mg each of nuclear extracts from resting
PBL (day 0), or PHA activated PBL (days 1±7)
were used for EMSA with end-labeled A/B
probe. Reaction mixtures were separated on
a 8% nondenaturing polyacrylamide gel. Pro-
tein complexes binding to the A/B oligonucle-
otide are indicated by arrows.
(C) 1 mg of nuclear extract from PHA activated
day 7 PBL was included in EMSA for lanes
2±7, and the A/B probe was used for lanes
1±7. 4 mg of individual antibodies were added
to the assay as indicated. The reaction mix-
tures were separated on a 6% nondenaturing
gel to resolve the supershifted complexes.
(D) 1 mg each of nuclear extract from PHA
activated day 7 PBL, Jurkat, Hut78, JY, and
HeLa cells, and A probe was used for EMSA.
synergistic. Thus, NF-kB is more potent than RFLAT-1 RFLAT-1 Is a Developmentally Regulated Protein
in T Lymphocytesas a transactivator of RANTES gene expression in fibro-
blasts, while the reverse is true in T cells. RFLAT-1 is the first late T cell transcription factor identi-
fied to date. However, as shown by Northern analysis,
RFLAT-1 is widely expressed. The ubiquitous expres-Discussion
sion of RFLAT-1 suggests that it may play a more general
role in transcriptional regulation, and that additionalRANTES is a chemoattractant molecule that plays a
pivotal role in both acute and chronic inflammation and mechanisms may further modulate its activity. For ex-
ample, in cell lines that do not express RANTES, such ascan block HIV infection in vitro. In normal T cells, expres-
sion of the RANTES gene is late, 3±5 days after activa- Jurkat, HeLa, and resting fibroblasts, RFLAT-1 protein is
detected in the nucleus by Western blotting, but nucleartion. In the context of an immune response, late RANTES
expression may be important in amplification and propa- extracts do not contain material that binds to the RANTES
A site (Figure 5D; data not shown). These results suggestgation of an inflammatory state (Ortiz et al., 1995). How-
ever, until recently, little was known about the molecular that the regulation of RFLAT-1 activity, at least at the
level of DNA binding, is complicated. Our results alsomechanisms underlying the induction of genes at this
late stage of T cell activation (Ortiz et al., 1997). Charac- indicate that during T cell activation, RFLAT-1 function
is regulated mainly at the protein level. The steady-stateterization of the transcriptional regulation of RANTES
in T cells will help us understand largely unexplored level of the RFLAT-1 message does not change during
T cell maturation, indicating that RFLAT-1 expression ismolecular mechanisms underlying gene expression.
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Figure 6. The RFLAT-1 Protein Is Induced
Late in Activated T Cells
(A) Northern analysis of RFLAT-1 expression
in T cell activation. 20 mg of total RNA from
resting PBL (day 0) and PHA activated PBL
(days 1±7) were isolated and separated on a
1% formaldehyde-agarose gel and trans-
ferred onto a nylon membrane. The mem-
brane was hybridized with [a32P] randomly la-
beled RFLAT-1 cDNA probe under stringent
conditions. The 28s rRNA of each sample was
visualized by ethidium bromide staining to
normalize for the amount of RNA loaded.
(B) Western analysis of RFLAT-1 in nuclear
and cytoplasmic extracts of activated T cells.
Nuclear or cytoplasmic extracts from resting
PBL (day 0), and PHA activated PBL (day 1±7),
Jurkat, Hut78, and JY were isolated. 200 mg
of each sample were subjected to SDS-PAGE
and immunoblotted with antigen purified anti-
RFLAT-1. As loading controls, the nuclear
blot was reprobed with a monoclonal anti-
body against nuclear pore complex protein
(NPCP); the cytoplasmic blot with a mono-
clonal anti-a-actinin.
(C) Western analysis of p50 in activated T
cells. 50 mg of each of the samples described
in (B) were prepared for Western blotting us-
ing anti-p50.
(D) Western analysis of p65 in activated T
cells. Similar blots as described in (C) were
probed with anti-p65.
not transcriptionally controlled. Nevertheless, Western binds to the A site, while Rel proteins bind to the B and
probably the A sites. The A/B site resides between theanalysis shows that the RFLAT-1 protein is detected in
both nuclear and cytoplasmic fractions only 3 days after CCAAT and TATAAA boxes, bringing RFLAT-1 and Rel
proteins in close proximity to the basal transcriptionalT cell activation and increases further by day 7, sug-
gesting that RFLAT-1 protein synthesis is induced devel- machinery. However, whether RFLAT-1, Rel proteins,
and basal transcription factors indeed physically inter-opmentally during T cell activation. Alternatively, the
late appearance of RFLAT-1 may also be due to other act with each other remains unclear.
posttranslational mechanisms.
Is RANTES Expression in T Cells Controlled
by an Enhanceosome?RFLAT-1 Is a Member of the Zinc Finger
Protein Superfamily RANTES gene expression is regulated through distinct
mechanisms in T cells and other cell types. In fibroblastsZinc finger motifs have been identified in a number of
DNA binding factors and other regulatory proteins and epithelial cells, RANTES is induced immediately
(within hours) by proinflammatory stimuli such as TNF-a(Mitchell and Tjian, 1989). Since RFLAT-1 contains three
tandem TFIIIA-like zinc fingers located at the C terminus, and IL-1b. This rapid induction allows the immediate
attraction of blood leukocytes to the site of inflammationit belongs to the Sp1-like superfamily. Unlike Sp1 and
more closely related proteins, RFLAT-1 does not contain and is most likely achieved by the binding of Rel pro-
teins, and possibly other early response factors, to thea highly conserved glutamine-rich transactivation do-
main (Courey et al., 1989). Instead, a putative transacti- promoter. Compared to non-T cells, the upregulation of
RANTES expression in activated T cells is more complexvation domain rich in proline and alanine residues is
present at the N terminus. While the overall structure and is developmentally controlled. First, a variety of tran-
scription factors are involved, including both early fac-of RFLAT-1 is similar to erythroid KruÈ ppel-like factors
(EKLF, BTEB, EZF), on the protein level, its putative tors (Rel proteins) and late regulated DNA binding pro-
teins (RFLAT-1 and others). These factors may synergizetransactivation domain does not show any obvious se-
quence similarity to them or other proline-rich domain to induce RANTES expression as shown for RFLAT-1
and Rel proteins. Second, as a transactivator, RFLAT-1containing proteins. Proline-rich domains may contain
discrete activation and repression subdomains (Chen requires not only its own cis-acting element, but also
intact adjacent, and even distal, DNA segments in orderand Bieker, 1996; Yet et al., 1998). They can also mediate
protein-protein interactions as shown for the associa- to exert its effect. Together, these findings support an
enhanceosome model for RANTES gene transcriptiontion of the TFIIB component of the basal transcription
machinery, and TBP-associated factors (TAF) with other in T cells (Miyamoto et al., unpublished data).
An enhanceosome is a nuclear protein complex as-transcriptional activators (Kim and Roeder, 1994; Chiang
and Roeder, 1995). In the RANTES promoter, RFLAT-1 sembled at a given enhancer to confer a network of
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Figure 7. RFLAT-1 Is a Transactivator for the
RANTES Gene
(A) RFLAT-1 transactivates the RANTES gene
in Jurkat T cells. 10 mg of the pcDNA3.1 (open
bars) or pcDNA3.1-RFLAT-1 (solid bars) plas-
mids were electroporated into Jurkat cells to-
gether with 10 mg of luciferase reporter con-
structs derived from the RANTES promoter.
R: pGL2-R-luciferase containing the complete
200 bp RANTES promoter region immediately
upstream of the transcription start site. A-,
B-, A/B-, E-, and C-: reporter gene constructs
derived from pGL2-R-luciferase with either
the A, B, A/B, E, or C site replaced by non-
sense oligonucleotides. (AB)3: pGL2-SV40-
(AB)3-Luciferase. Thirty-six hours after electro-
poration, cells were harvested for luciferase
assays.
(B) RFLAT-1 transactivates the RANTES gene
in NIH3T3 fibroblasts. 5 mg of the pcDNA3.1
(open bars) or pcDNA3.1-RFLAT-1 (solid bars)
plasmids were introduced into NIH3T3 cells
together with 5 mg of luciferase reporter gene
constructs: R, A-, B-, A/B-, E-, C-, or (AB)3.
Thirty-six hours after transfection, cells were
harvested and luciferase activity was mea-
sured.
(C) Cotransfection of RFLAT-1 and Rel genes in Jurkat T cells. Jurkat cells were transfected with 10 mg of pGL2-R-luciferase, together with
10 mg of pcDNA3.1-RFLAT-1, 10 mg of pcDNA3.1-p50, 10 mg of pcDNA3.1-p65, or 10 mg of each of the three plasmids in different combinations.
For each transfection, the total plasmid amount was equal (40 mg) and was achieved by using the empty vector pcDNA3.1 as compensation.
(D) Cotransfection of RFLAT-1 and Rel genes in NIH3T3 fibroblasts. Similar cotransfections as described in Figure 7C were performed in
NIH3T3 cells, except 5 mg of each plasmid was used, and the total plasmid amount for each transfection was 20 mg. Data in figure 7 is
presented as the mean 6 SD of triplicate transfections or the mean of duplicate transfections and represent at least three independent
experiments.
protein-protein and protein-DNA interactions. The in- cells, but whether they physically interact still remains
to be determined.teractions of the various components of an enhanceo-
some allow cooperativity and transcriptional synergy
(Carey, 1998). The enhanceosome model for the RANTES Conclusions
We have identified and characterized a novel transcrip-gene best explains the findings to date, including its
unique and precise expression pattern in T cells. In addi- tion factor that regulates RANTES expression in T lym-
phocytes. This is the first late T cell transactivator de-tion to gene activators, DNA-bending proteins such as
HMG(I/Y) also participate in the enhanceosome struc- scribed. RFLAT-1 and its cis-acting binding sequence
provide a potentially interesting new target for immuno-ture, probably by binding to the E site (Song et al.,
unpublished data). Further characterization of the pro- therapy. Downregulating RANTES expression may prove
useful as a therapy for a variety of autoimmune andposed RANTES enhanceosome will require identifica-
tion of other late proteins that bind to the C and E sites. other inflammatory diseases, while upregulating RANTES
expression may prove therapeutic for AIDS or cancer.Rel proteins are known activators for a wide range
of genes. They also play important roles for RANTES
Experimental Proceduresexpression, as shown by our group and others (Nelson
et al., 1996; Moriuchi et al., 1997). The interaction and
Nuclear Extract Preparation and Southwestern Blottingsynergy of Rel proteins with other proteins is clear.
Human PBL were isolated over Ficoll-Hypaque (ICN Biomedicals,
NF-kB and NFAT interact to coordinately activate IFN-g Inc., Costa Mesa, CA). Cells (2 3 106/ml) were stimulated with 5
gene transcription (Sica et al., 1997). NF-kB and STAT1 mg/ml PHA (DIFCO, Detroit, MI) in RPMI Medium 1640 (Irvine Scien-
tific, Santa Ana, CA) supplemented with 10% FCS (HyClone, Logan,are thought to mediate the synergistic effect of TNF-a
UT)/2 mM L-glutamine, 100 U/ml penicillin, and 100 mg/ml strepto-and IFN-g by cooperatively activating the expression of
mycin (Irvine Scientific, Santa Ana, CA) for up to 7 days. NuclearIRF-1 (Ohmori et al., 1997). In T cell activation, NF-kB
and cytosolic extracts were prepared as described (Durand et al.,is well documented as an immediate early gene (within
1988), with minor modifications (Ortiz et al., 1996). The protein con-
30 min) that activates early genes such as interleukin-2 centration of the extracts was determined by Bradford assay using
(Crabtree, 1989; Ullman et al., 1990), but its expression the Bio-Rad protein assay reagent. 50 mg of each nuclear extract
was separated by 10% SDS-PAGE and the proteins were transferredand role in late activation stages of T cells has not been
onto a PVDF membrane. The membrane was then subjected to apreviously examined. In this report, we investigated the
denaturation-renaturation procedure by incubation in binding bufferkinetics of the NF-kB protein in a later time frame and
(10 mM Tris-Cl [pH 7.5], 80 mM NaCl, 1 mM EDTA, 1 mM dithiothrei-found that both the p50 and p65 subunits are upregu-
tol, and 1% glycerol) supplemented with decreasing amounts of
lated late during cellular activation. The coexistence of guanidine (6 M, 4.5 M, 2.25 M, 1.13 M, 0.56 M, 0.28 M, 0.14 M, and
RFLAT-1 and NF-kB provides supporting evidence for 0 M) at 08C. The membrane was blocked with 5% non-fat milk
in binding buffer, hybridized with 32P end-labeled oligonucleotidetheir synergistic effect on the RANTES promoter in T
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(0.1±0.2 pmole/ml in 0.25% non-fat milk in binding buffer) at 258C concentrated. His6-RFLAT-1 was injected into rabbits to generate
polyclonal antibodies. Anti-RFLAT-1 antiserum was purified over afor 5 hr, washed, and exposed to Amersham Hyperfilm.
protein A column followed by an antigen column. For Western blots
of transfected cells, cultures were harvested 36 hr after transfectionLibrary Construction and Screening
and nuclear extracts were prepared according to Andrews and FallerPBL were cultured with PHA-P for 5 days and total RNA was ex-
(1991). For PBL and other cell lines, nuclear extracts were preparedtracted (Chomczynski and Sacchi, 1987). Poly(A)1 RNA was further
as described above. Anti-RFLAT-1 Western blotting was performedisolated using a QIAGEN kit (QIAGEN Inc., Santa Clarita, CA). 5 mg
as follows: membranes were blocked in 5% non-fat milk in TBSTof poly(A)1 RNA was used to construct a lgt11 library using the
(0.02 M Tris-HCl [pH 7.4], 0.5 M NaCl, and 0.2% Tween-20), washedSuperScript Choice System (Life Technologies, Gaithersburg, MD).
with TBST, and incubated in blocking buffer containing antigen puri-The recombinant l phage were packaged with GigapackIII Gold
fied anti-RFLAT-1 (1:1000 [v/v]). The membranes were then washed,Packaging Extract (Stratagene, La Jolla, CA) and amplified. For ex-
incubated in blocking buffer with horseradish peroxidase-conju-pression cloning, l phage plaques were induced with IPTG at 378C
gated goat anti-rabbit antibodies (1:10,000 [v/v]), washed, detectedfor 6 hr and transferred to PVDF membranes. The denaturation-
by ECL (Amersham, Arlington Heights, IL), and exposed to Amer-renaturation treatment and hybridization protocol was the same as
sham Hyperfilm. Anti-p50 and anti-p65 Western blotting was per-that for Southwestern blotting except that hybridization was only
formed following the manufacturer's instructions. In vitro transcrip-for 1 hr at 258C, and the binding buffer was supplemented with 10
tion/translation assays were performed using the TNT Quickmg/ml of denatured, sonicated calf thymus DNA. A total of 6 3
Coupled Transcription/Translation System (Promega, Madison, WI)106 (33 library complexity) plaques were screened with a 32P end-
following the instructions.radiolabeled A3 oligonucleotide. The oligonucleotide sequence was
GGGAATTCGAATTCGCTATTTTGGAAACTCCCCTTAGGGCTATTT
TGGAAACTCCCCTTAGGGCTATTTTGGAAACTCCCCTTAGGCTC Immunostaining and EMSA
GAGCTCGAGGG. Positive phage clones were isolated and phage 1 3 104 cells were adhered to 8-well slides (Electron Microscopy
DNA was purified with a Wizard Lambda Preps DNA Purification Sciences, Ft. Washington, PA) and fixed in methanol followed by
System (Promega, Madison, WI). The cDNAs were excised from the acetone. The wells were incubated in blocking buffer (5% goat se-
lgt11 vector by restriction digestion and subcloned into a plasmid rum, 5% horse serum, and 0.1% Triton X-100 in PBS), washed in
vector for sequencing. The same library was used for DNA-DNA PBS supplemented with 0.1% Triton X-100, and incubated with
screening following the protocols described by Ausubel et al., 1989. antigen purified rabbit polyclonal anti-RFLAT-1 (1:500 [v/v]) or rabbit
2.4 3 106 plaques were screened with a 32P randomly labeled 880 IgG (1:500 [v/v]) (Santa Cruz Biotechnology, Santa Cruz, CA). The
bp cDNA fragment from RFLAT-1 to obtain the 1430 bp complete wells were washed, incubated with goat anti-rabbit FITC (1:2000
sequence. [v/v]) (Caltag, Burlingame, CA) and anti-FITC Alexa 488 (1:2000 [v/
v]) (Molecular Probes, Eugene, OR). Finally, the slide was washed
Northern Blotting with PBS, covered with mounting media (1:3 [v/v], Vectashield with
Total RNA and poly(A)1 RNA was isolated as described above. propidium iodide) (Vector, Burlingame, CA), cover slipped, and
Multi-human tissue blots with poly(A)1 RNA were purchased from sealed. EMSA and supershift assays were performed essentially as
Clontech (Palo Alto, CA). Using Clontech ExpressHyb Hybridization described by Ortiz et al. (1996). Oligonucleotides were synthesized
solution, Northern blots were probed with the RFLAT-1 cDNA frag- by Life Technologies, Inc. (Gaithersburg, MD) and purified by a
ment or human b-actin cDNA under high-stringency conditions ac- polyacrylamide-urea gel. Oligonucleotides were end-labeled using
cording to the manufacturer's instructions. [g-32P]ATP and T4 polynucleotide kinase. The following oligonucleo-
tides were used:
Transient Transfections and Luciferase A/B, AATTCGCTATTTTGGAAACTCCCCTTAGGGGATGCCCCTC
Reporter Gene Assays AACTGCG; A, AATTCGTTGCTATTTTGGAAACTCCCCTTG; B, AATT
A series of RANTES promoter pGL2-luciferase reporter constructs CGCTAGGGGATGCCCCTCAACTGCG; E, AATTCTTTGTGCAATTT
were described previously (Nelson et al., 1993; Ortiz et al., 1996). CACTTATGATACCG; C, AATTCTCTAGATGAGAGAGCAGTGAGGG
RFLAT-1 cDNA (EcoRI fragment) was excised from the lgt11 vector AGAGACG; and kB, AATTCGTCAGAGGGGACTTTCCGAGAG.
and subcloned into the CMV-promoter-driven mammalian expres- Anti-Sp1, anti-Sp3, anti-p65, and anti-c-rel were purchased from
sion vector pcDNA3.1(1) (Invitrogen, San Diego, CA). p65 cDNA Santa Cruz Biotechnology (Santa Cruz, CA). Anti-p50, anti-p65, and
(HindIII-BamHI fragment) and p50 cDNA (HindIII±XbaI fragment) anti-a-actinin were from Upstate Biotechnology (Lake Placid, NY).
were excised from pBluescript vector (gifts from G. Nolan, Stanford Anti-NPCP was from BAbCO (Berkeley, CA).
University) and subcloned into pcDNA 3.1. COS-7 and NIH3T3 fibro-
blasts were transiently transfected by the calcium phosphate
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